NVS•benzinga•
Novartis Announces Presentation Of 17 Abstracts At 2025 AAAAI/WAO And AAD Meetings, Featuring Phase III REMIX-1/2 Data On Remibrutinib For Chronic Urticaria, Long-Term Cosentyx Data In Hidradenitis Suppurativa, And Phase II Patient Outcomes For Remibrutin
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 28, 2025 by benzinga